【摘要】：目的觀察吡格列酮對炎癥性腸病小鼠血清腫瘤壞死因子-α(TNF-α)與高敏C反應(yīng)蛋白(hs-CRP)水平的影響,探討吡格列酮可能成為治療炎癥性腸病的藥物及降低遠期動脈粥樣硬化的發(fā)病風(fēng)險。方法清潔BALB/c小鼠隨機分為3組,分別為正常組、模型組、吡格列酮藥物干預(yù)組。采用3%DSS溶液制備炎癥性腸病小鼠模型,在造模第2天開始給予吡格列酮25 mg/kg灌胃,每天一次,直至實驗結(jié)束。治療結(jié)束后,采用酶聯(lián)免疫法(ELISA法)檢測血清hs-CRP、TNF-α。結(jié)果與正常組相比較,模型組小鼠腸組織出現(xiàn)炎癥性表現(xiàn),且血清hs-CRP、TNF-α的水平均顯著增高(P0.01);與模型組相比較,吡格列酮干預(yù)組小鼠腸道炎癥表現(xiàn)明顯減輕,且血清hs-CRP、TNF-α的水平均顯著降低(P0.01)。結(jié)論吡格列酮能下調(diào)炎癥性腸病小鼠TNF-α的表達,減輕腸道炎癥性改變,并改善腸道組織形態(tài)結(jié)構(gòu),而發(fā)揮治療,明顯降低血清hs-CRP的水平,降低遠期動脈粥樣硬化的風(fēng)險。
[Abstract]:Objective to observe the effect of pioglitazone on serum levels of tumor necrosis factor- 偽 (TNF- 偽) and Gao Min C-reactive protein (hs-CRP) in mice with inflammatory bowel disease. To explore the possibility of pioglitazone as a drug for inflammatory bowel disease and to reduce the risk of long-term atherosclerosis. Methods Clean BALB/c mice were randomly divided into 3 groups: normal group, model group and pioglitazone intervention group. The model of inflammatory bowel disease was established in mice with 3%DSS solution. Pioglitazone was given orally for 25 mg/kg on the second day until the end of the experiment. After treatment, serum hs-CRP,TNF- 偽 was detected by enzyme linked immunosorbent assay (ELISA). Results compared with the normal group, the intestinal tissue of the model group showed inflammatory manifestations, and the level of serum hs-CRP,TNF- 偽 increased significantly (P0.01). Compared with the model group, the intestinal inflammation in pioglitazone treated group was obviously alleviated, and the serum hs-CRP,TNF- 偽 level was significantly decreased (P0.01). Conclusion pioglitazone can down-regulate the expression of TNF- 偽 in mice with inflammatory bowel disease, alleviate the inflammatory changes in the intestine and improve the morphology of intestinal tissue. The treatment of pioglitazone can significantly reduce the level of serum hs-CRP. Reduce the risk of long-term atherosclerosis.
【作者單位】： 山西醫(yī)科大學(xué)第一醫(yī)院;
【分類號】：R574

【共引文獻】

相關(guān)期刊論文 前10條

1 黃利興;謝勇;;脂氧素在炎癥性腸病中的作用機制[J];廣東醫(yī)學(xué);2014年17期

2 陳曉琳;唐成林;謝輝;唐念珍;郜婕;劉仁建;;電針對非酒精性脂肪性肝病大鼠肝TLR4、NF-κB表達的影響[J];南方醫(yī)科大學(xué)學(xué)報;2014年11期

3 張一娜;王莉;劉向娟;俞春江;程露楊;;急性腦梗死患者高遷移率族蛋白B1和過氧化小體增殖劑激活型受體γmRNA的表達[J];中國腦血管病雜志;2011年07期

4 賈玉臣;陳慶森;;乳源酪蛋白糖巨肽改善小鼠潰瘍性結(jié)腸炎的研究[J];食品科學(xué);2010年21期

5 賈玉臣;陳慶森;馮毅楠;徐怡君;李洋;;乳源酪蛋白糖巨肽對潰瘍性結(jié)腸炎小鼠MUC2表達的影響[J];食品科學(xué);2011年15期

6 甘華田;;正確選擇炎癥性腸病實驗研究的動物模型[J];胃腸病學(xué);2007年03期

7 李霞;鐘捷;;炎癥性腸病動物模型研究進展[J];胃腸病學(xué);2009年09期

8 李霞;孫t，

本文編號：2295602